Gilead strikes $4.9B Forty Seven acquisition, paying a hefty premium for cancer drug

Gilead has struck a deal to buy Forty Seven for $4.9 billion. The takeover will give Gilead control of midphase anti-CD47 antibody magrolimab that delivered data that impressed investors late last year.